Stock Scorecard
Stock Summary for Allogene Therapeutics Inc (ALLO) - $1.23 as of 10/24/2025 7:03:31 PM EST
Total Score
11 out of 30
Safety Score
36 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALLO
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALLO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALLO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ALLO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ALLO (36 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ALLO
Financial Details for ALLO
Company Overview |
|
|---|---|
| Ticker | ALLO |
| Company Name | Allogene Therapeutics Inc |
| Country | USA |
| Description | Allogene Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of next-generation allogeneic T-cell therapies designed to target various forms of cancer. Leveraging its proprietary technology platform, Allogene aims to deliver transformative immuno-oncology treatments that enhance the body’s natural ability to fight cancer while minimizing associated treatment risks and complexities. With a strong pipeline of candidates and a dedicated focus on advancing therapeutic solutions, Allogene is positioned to significantly impact the oncology landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/30/2025 |
Stock Price History |
|
| Last Day Price | 1.23 |
| Price 4 Years Ago | 14.92 |
| Last Day Price Updated | 10/24/2025 7:03:31 PM EST |
| Last Day Volume | 1,647,653 |
| Average Daily Volume | 3,157,769 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.86 |
| Last Price to 52 Week Low | 43.02% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.95 |
| Sector PE | 41.12 |
| 5-Year Average PE | -3.25 |
| Free Cash Flow Ratio | 5.13 |
| Industry Free Cash Flow Ratio | 14.54 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 8.92 |
| Total Cash Per Share | 0.24 |
| Book Value Per Share Most Recent Quarter | 1.56 |
| Price to Book Ratio | 0.83 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 11,631.14 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 221,881,000 |
| Market Capitalization | 272,913,630 |
| Institutional Ownership | 74.03% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 21.29% |
| Reported EPS 12 Trailing Months | -1.10 |
| Reported EPS Past Year | -0.51 |
| Reported EPS Prior Year | -1.33 |
| Net Income Twelve Trailing Months | -236,908,000 |
| Net Income Past Year | -257,590,000 |
| Net Income Prior Year | -327,265,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 52,332,000 |
| Total Cash Past Year | 75,218,000 |
| Total Cash Prior Year | 83,155,000 |
| Net Cash Position Most Recent Quarter | 52,332,000 |
| Net Cash Position Past Year | 75,218,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 422,179,000 |
| Total Stockholder Equity Prior Year | 512,233,000 |
| Total Stockholder Equity Most Recent Quarter | 344,561,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -173,601,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.78 |
| Free Cash Flow Past Year | -200,994,000 |
| Free Cash Flow Prior Year | -239,249,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.01 |
| MACD Signal | 0.03 |
| 20-Day Bollinger Lower Band | 1.01 |
| 20-Day Bollinger Middle Band | 1.21 |
| 20-Day Bollinger Upper Band | 1.41 |
| Beta | 0.43 |
| RSI | 44.15 |
| 50-Day SMA | 1.60 |
| 150-Day SMA | 3.28 |
| 200-Day SMA | 5.21 |
System |
|
| Modified | 10/24/2025 5:01:54 PM EST |